IL18 and COVID-19: Using the data presented here on IgM SARS-CoV-2 peptide reactivity and serum cytokine levels of IL-1α, IL-6, and IL-18, we have identified a unique biomarker panel which could be used for early identification of COVID-19 patients with increased risk of severe and potentially fatal disease (Figure 7).